Mark Alexander MacLean
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Mark Alexander MacLean has a total of 261 co-authors. Here are the top co-authors by number of shared publications:
- Alon Friedman
Department of Medical Neuroscience and the Brain Repair Center, Faculty of Medicine, Dalhousie University, Halifax, Canada
5 shared publications - Michael Anthony Rizzuto
University of British Columbia
5 shared publications - Sean Christie
Dalhousie University
4 shared publications Sean D. Christie
Dalhousie University
4 shared publicationsArjun Sahgal
Sunnybrook Health Sciences Centre
3 shared publicationsCordula Netzer
University Hospital of Basel
3 shared publications
Latest Publications
- 16 June 2026
- Published by Cambridge University Press (CUP) in Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
- p. 1
Reviewer Comment on Nguyen et al. “Postoperative Complications after Lumbar Spinal Surgery in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis”
- 16 June 2026
- Published by Cambridge University Press (CUP) in Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
- p. 1
Reviewer Comment on Nguyen et al. “Postoperative Complications after Lumbar Spinal Surgery in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis”
- Open Access
- 17 February 2026
- Published by Cambridge University Press (CUP) in Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
- p. 1-5
Assessment of Driving Restrictions Following Craniotomy: A Survey of Canadian Neurosurgeons
Background: Patients undergoing craniotomy experience a higher risk of seizures in the ensuing months. Consensus is lacking regarding the appropriate timeframe for safe return to driving following craniotomy in patients not otherwise limited by neurological deficits or a history of epilepsy. Methods: The Canadian Neurosurgery Research Collaborative (CNRC) distributed an anonymous, voluntary, electronic cross-sectional survey via SurveyMonkey to Canadian neurosurgeons. The survey comprised 16 questions designed to assess practice variations regarding recommendations for return to driving following craniotomy, stratified according to pathological diagnosis. Results: Forty-eight Canadian neurosurgeons responded to the survey. Driving recommendations varied greatly, with most surgeons recommending return to driving within one month of the craniotomy. The rationale behind these restrictions varied widely, consistent with the lack of evidence-based data to guide decision-making. Conclusion: This study emphasizes the lack of standardized practices regarding return to driving recommendations for patients undergoing craniotomy without prior seizures. Development of national return to driving guidelines would assist Canadian clinicians in making informed decisions regarding the optimal timeframe for the safe return to driving.
- 17 February 2026
- Published by Cambridge University Press (CUP) in Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
- p. 1-5
Open AccessAssessment of Driving Restrictions Following Craniotomy: A Survey of Canadian Neurosurgeons
Background: Patients undergoing craniotomy experience a higher risk of seizures in the ensuing months. Consensus is lacking regarding the appropriate timeframe for safe return to driving following craniotomy in patients not otherwise limited by neurological deficits or a history of epilepsy. Methods: The Canadian Neurosurgery Research Collaborative (CNRC) distributed an anonymous, voluntary, electronic cross-sectional survey via SurveyMonkey to Canadian neurosurgeons. The survey comprised 16 questions designed to assess practice variations regarding recommendations for return to driving following craniotomy, stratified according to pathological diagnosis. Results: Forty-eight Canadian neurosurgeons responded to the survey. Driving recommendations varied greatly, with most surgeons recommending return to driving within one month of the craniotomy. The rationale behind these restrictions varied widely, consistent with the lack of evidence-based data to guide decision-making. Conclusion: This study emphasizes the lack of standardized practices regarding return to driving recommendations for patients undergoing craniotomy without prior seizures. Development of national return to driving guidelines would assist Canadian clinicians in making informed decisions regarding the optimal timeframe for the safe return to driving.
- Open Access
- 11 November 2025
- Published by Wolters Kluwer Health in Spine
- Vol. 50 (24) , 1683-1691
An International Delphi Consensus on Defining the Optimal Surgical Composite Outcome in Metastatic Spine Disease
Study Design.: Delphi consensus. Objective.: To define an optimal surgical composite outcome measure in patients with metastatic spine disease (OSCO-M) through international consensus among key opinion leaders. Materials and Methods.: Members of the AO Spine Knowledge Forum Tumor, an international group of dedicated spine oncology surgeons and oncologists, participated in a modified Delphi process between March 2023 and November 2024. The study was conducted in 2 parts. The first part aimed on identifying which outcome variables were deemed important to be included in the composite outcome. The second part focused on the definition of a successful outcome with regards to the agreed variables from Part 1. Each part consisted of a questionnaire and a consensus meeting. Consensus was achieved when a threshold of 70% agreement was reached. Results.: A total of 42 dedicated spine oncology surgeons and oncologists from North America, Latin America, Europe, and Asia participated. Over 87% of respondents agreed that composite measures reflect the multidimensional aspect of the surgical process more than an individual outcome variable. Most respondents (93%) agreed/strongly agreed that composite measures should be used to assess the quality of surgical care in spine oncology. Through consensus, the following three outcome variables were selected to define the OSCO-M: the absence of SAVES-V2 (Spinal Adverse Events Severity System, Version 2) grade 3 adverse events or higher within 30 days of surgery, maintaining or improving ECOG (Eastern Cooperative Oncology Group) performance status at 90 days, and being ambulatory (with or without aid) at 90 days. Conclusion.: This is the first study defining a composite outcome measure in oncologic surgery for spinal metastases derived from an international group of key opinion leaders in spine oncology. The OSCO-M may be useful for future research in spine tumor patients and serve as a benchmark to optimize outcomes.
- 11 November 2025
- Published by Wolters Kluwer Health in Spine
- Vol. 50 (24) , 1683-1691
Open AccessAn International Delphi Consensus on Defining the Optimal Surgical Composite Outcome in Metastatic Spine Disease
Study Design.: Delphi consensus. Objective.: To define an optimal surgical composite outcome measure in patients with metastatic spine disease (OSCO-M) through international consensus among key opinion leaders. Materials and Methods.: Members of the AO Spine Knowledge Forum Tumor, an international group of dedicated spine oncology surgeons and oncologists, participated in a modified Delphi process between March 2023 and November 2024. The study was conducted in 2 parts. The first part aimed on identifying which outcome variables were deemed important to be included in the composite outcome. The second part focused on the definition of a successful outcome with regards to the agreed variables from Part 1. Each part consisted of a questionnaire and a consensus meeting. Consensus was achieved when a threshold of 70% agreement was reached. Results.: A total of 42 dedicated spine oncology surgeons and oncologists from North America, Latin America, Europe, and Asia participated. Over 87% of respondents agreed that composite measures reflect the multidimensional aspect of the surgical process more than an individual outcome variable. Most respondents (93%) agreed/strongly agreed that composite measures should be used to assess the quality of surgical care in spine oncology. Through consensus, the following three outcome variables were selected to define the OSCO-M: the absence of SAVES-V2 (Spinal Adverse Events Severity System, Version 2) grade 3 adverse events or higher within 30 days of surgery, maintaining or improving ECOG (Eastern Cooperative Oncology Group) performance status at 90 days, and being ambulatory (with or without aid) at 90 days. Conclusion.: This is the first study defining a composite outcome measure in oncologic surgery for spinal metastases derived from an international group of key opinion leaders in spine oncology. The OSCO-M may be useful for future research in spine tumor patients and serve as a benchmark to optimize outcomes.
- 24 October 2025
- Published by Cambridge University Press (CUP) in Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
- p. 1-8
Return to Driving after a Craniotomy: A Systematic Review and Evidence-Based Approach
Background: Patients undergoing craniotomy experience a higher risk of seizures in the ensuing months. Consensus is lacking regarding the appropriate timeframe for safe return to driving following craniotomy in patients not otherwise limited by neurological deficits or a history of epilepsy. Methods: We performed a systematic literature review on driving recommendations post-craniotomy. We then performed a scoping review on the risk of seizure post-craniotomy and used risk calculations and accepted risk thresholds from the epilepsy literature to develop an evidence-based approach to driving recommendations post-craniotomy. Results: The systematic review of driving recommendations revealed national guidelines (the United Kingdom, New Zealand, Australia). We transposed risk calculations and accepted risk thresholds from the epilepsy literature (accident risk ratio [ARR] < 2; chance of occurrence of a seizure in the next year < 20%) to patients who undergo a craniotomy. Using data from a large meta-analysis of seizure risk post-craniotomy, we calculated ARRs for various underlying pathologies at different postoperative timepoints and compared them with accepted risk thresholds from the epilepsy literature. We determine that patients who undergo a craniotomy for a higher-risk condition (like high-grade glioma) may resume driving after at least 1 month without seizure, whereas those patients undergoing a craniotomy for lower-risk conditions (like infratentorial pathology) may resume driving without consideration for the risk of seizure. Conclusion: This systematic review of the literature and evidence-based approach to risk threshold calculations derived from the epilepsy literature provides a preliminary framework to guide clinicians regarding recommendations for return to driving following craniotomy.
- 24 October 2025
- Published by Cambridge University Press (CUP) in Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
- p. 1-8
Return to Driving after a Craniotomy: A Systematic Review and Evidence-Based Approach
Background: Patients undergoing craniotomy experience a higher risk of seizures in the ensuing months. Consensus is lacking regarding the appropriate timeframe for safe return to driving following craniotomy in patients not otherwise limited by neurological deficits or a history of epilepsy. Methods: We performed a systematic literature review on driving recommendations post-craniotomy. We then performed a scoping review on the risk of seizure post-craniotomy and used risk calculations and accepted risk thresholds from the epilepsy literature to develop an evidence-based approach to driving recommendations post-craniotomy. Results: The systematic review of driving recommendations revealed national guidelines (the United Kingdom, New Zealand, Australia). We transposed risk calculations and accepted risk thresholds from the epilepsy literature (accident risk ratio [ARR] < 2; chance of occurrence of a seizure in the next year < 20%) to patients who undergo a craniotomy. Using data from a large meta-analysis of seizure risk post-craniotomy, we calculated ARRs for various underlying pathologies at different postoperative timepoints and compared them with accepted risk thresholds from the epilepsy literature. We determine that patients who undergo a craniotomy for a higher-risk condition (like high-grade glioma) may resume driving after at least 1 month without seizure, whereas those patients undergoing a craniotomy for lower-risk conditions (like infratentorial pathology) may resume driving without consideration for the risk of seizure. Conclusion: This systematic review of the literature and evidence-based approach to risk threshold calculations derived from the epilepsy literature provides a preliminary framework to guide clinicians regarding recommendations for return to driving following craniotomy.
- Open Access
- 29 June 2025
- Published by Taylor & Francis in Expert Review of Neurotherapeutics
- Vol. 25 (8) , 991-1006
N-Methyl-D-Aspartate receptor antagonist treatment in traumatic brain injury: a systematic review of the clinical studies
Traumatic brain injury (TBI) is a leading cause of long-term disability. N-methyl-D-aspartate receptor (NMDAR) signaling constitutes an important target for pharmacological treatment options. The authors have systematically reviewed primary clinical literature reporting on FDA-approved NMDAR antagonist treatment in TBI, based on a set of pre-defined eligibility criteria. Risk of bias assessment was performed using Scottish Intercollegiate Guidelines Network (SIGN) recommendations. Patient characteristics, treatment conditions, and outcomes were reported according to PRISMA guidelines. This review of five clinical literature databases identified 32 eligible studies. Of 1,827 included patients, the majority (74.8%) experienced severe TBI (weighted mean baseline GCS 6.35). Amantadine (24 studies) variably influenced functional recovery and was linked to adverse effects. Ketamine (five studies) variably lowered intracranial pressure and suppressed spreading depolarization. Memantine and dextromethorphan (2 and 1 studies, respectively) showed favorable safety profiles, though data were limited. Across controlled studies, there was a 0.46 (95% CI: 0.16-0.76) weighted mean difference between control and intervention, favoring NMDAR antagonist treatment. Future trials should incorporate mechanism-driven biomarkers and must expand research on safe, well-tolerated drugs to improve efficacy and mitigate adverse effects.PROSPERO registration number: CRD42024539051.
- 29 June 2025
- Published by Taylor & Francis in Expert Review of Neurotherapeutics
- Vol. 25 (8) , 991-1006
Open AccessN-Methyl-D-Aspartate receptor antagonist treatment in traumatic brain injury: a systematic review of the clinical studies
Traumatic brain injury (TBI) is a leading cause of long-term disability. N-methyl-D-aspartate receptor (NMDAR) signaling constitutes an important target for pharmacological treatment options. The authors have systematically reviewed primary clinical literature reporting on FDA-approved NMDAR antagonist treatment in TBI, based on a set of pre-defined eligibility criteria. Risk of bias assessment was performed using Scottish Intercollegiate Guidelines Network (SIGN) recommendations. Patient characteristics, treatment conditions, and outcomes were reported according to PRISMA guidelines. This review of five clinical literature databases identified 32 eligible studies. Of 1,827 included patients, the majority (74.8%) experienced severe TBI (weighted mean baseline GCS 6.35). Amantadine (24 studies) variably influenced functional recovery and was linked to adverse effects. Ketamine (five studies) variably lowered intracranial pressure and suppressed spreading depolarization. Memantine and dextromethorphan (2 and 1 studies, respectively) showed favorable safety profiles, though data were limited. Across controlled studies, there was a 0.46 (95% CI: 0.16-0.76) weighted mean difference between control and intervention, favoring NMDAR antagonist treatment. Future trials should incorporate mechanism-driven biomarkers and must expand research on safe, well-tolerated drugs to improve efficacy and mitigate adverse effects.PROSPERO registration number: CRD42024539051.
- 20 May 2025
- Published by Springer Nature in Neurocritical Care
- Vol. 44 (1) , 50-55
Paroxysmal Cortical Slowing Predicts Posttraumatic Epilepsy After Severe Traumatic Brain Injury
Background The objective of this study was to evaluate whether paroxysmal slow wave events (PSWEs) identified in early electroencephalography (EEG) predict posttraumatic epilepsy (PTE) and disability outcomes following severe traumatic brain injury (sTBI). Methods A retrospective case–control study included 45 patients with sTBI (17 with PTE and 28 without PTE) matched by age and Glasgow coma scale. Clinical and EEG data were analyzed. Logistic regression and leave-one-out cross-validation (LOOCV) assessed PTE risk and disability. The area under the curve (AUC) measured accuracy. Results Patients with PTE had longer time in PSWEs (P = 0.04) and lower median power frequency (MPF) of PSWEs (P = 0.02) on initial EEGs, along with increased time in PSWEs between initial and follow-up EEGs (P = 0.03). Lower MPF was associated with increased PTE risk (odds ratio 5.88; P = 0.04). Multivariate regression identified hemicraniectomy, time in PSWEs, and MPF as PTE predictors (AUC 0.87; P < 0.0001), maintaining strong LOOCV performance (AUC 0.83; P < 0.0001, accuracy 80%). Longer time in PSWEs was observed in patients with severe disability at the 3-, 6-, and 12-month follow-ups compared with moderate-to-good recovery (P = 0.012, 0.006, and 0.04, respectively). Conclusions PSWEs predict PTE development and are more prevalent among patients with worse disability after sTBI. Quantitative PSWE analysis may guide preventive and therapeutic strategies for PTE.
- 20 May 2025
- Published by Springer Nature in Neurocritical Care
- Vol. 44 (1) , 50-55
Paroxysmal Cortical Slowing Predicts Posttraumatic Epilepsy After Severe Traumatic Brain Injury
Background The objective of this study was to evaluate whether paroxysmal slow wave events (PSWEs) identified in early electroencephalography (EEG) predict posttraumatic epilepsy (PTE) and disability outcomes following severe traumatic brain injury (sTBI). Methods A retrospective case–control study included 45 patients with sTBI (17 with PTE and 28 without PTE) matched by age and Glasgow coma scale. Clinical and EEG data were analyzed. Logistic regression and leave-one-out cross-validation (LOOCV) assessed PTE risk and disability. The area under the curve (AUC) measured accuracy. Results Patients with PTE had longer time in PSWEs (P = 0.04) and lower median power frequency (MPF) of PSWEs (P = 0.02) on initial EEGs, along with increased time in PSWEs between initial and follow-up EEGs (P = 0.03). Lower MPF was associated with increased PTE risk (odds ratio 5.88; P = 0.04). Multivariate regression identified hemicraniectomy, time in PSWEs, and MPF as PTE predictors (AUC 0.87; P < 0.0001), maintaining strong LOOCV performance (AUC 0.83; P < 0.0001, accuracy 80%). Longer time in PSWEs was observed in patients with severe disability at the 3-, 6-, and 12-month follow-ups compared with moderate-to-good recovery (P = 0.012, 0.006, and 0.04, respectively). Conclusions PSWEs predict PTE development and are more prevalent among patients with worse disability after sTBI. Quantitative PSWE analysis may guide preventive and therapeutic strategies for PTE.
- 28 April 2025
- Published by Elsevier in Neurosurgery Clinics of North America
- Vol. 36 (3) , 321-332
Fundamentals of Acute Care for Patients with Traumatic Spinal Cord Injury
- 28 April 2025
- Published by Elsevier in Neurosurgery Clinics of North America
- Vol. 36 (3) , 321-332
Fundamentals of Acute Care for Patients with Traumatic Spinal Cord Injury
- 23 April 2025
- Published by Wolters Kluwer Health in Neurosurgery
- Vol. 97 (5) , 1100-1107
Intracavitary Yttrium-90 Colloid Therapy for Cystic Sellar Masses: A Phase II Clinical Trial With 5-Year Follow-Up
BACKGROUND AND OBJECTIVES: Stereotactic intracavitary irradiation of cystic sellar masses (CSMs) with 90-Yttrium colloid (90Y) may mitigate significant morbidity and/or recurrence rates associated with traditional microsurgical resection. In this study, we aimed to prospectively assess the long-term effect of 90Y on tumor-cyst volume, endocrine, and vision outcomes after treatment of CSMs. METHODS: We conducted a Health Canada-approved, phase II, open label, prospective clinical trial. The primary indication for treatment was clinical evidence of mass effect on initial presentation or subsequent cyst enlargement. Patients underwent right frontal stereotactic insertion of 90Y (200 Gy to the cyst wall). Cyst volumes were measured using serial MRI. Visual field (VF) assessment and hypothalamic-pituitary hormone panel were obtained. Outcomes were collected postoperatively at 3, 9, and 24 months, then annually up to 5 years. RESULTS: Twenty-two patients (55% women, mean age = 63.6 years [SD 15.4]) received 90Y. The mean follow-up was 52 months (5-113). Primary diagnoses were the following: craniopharyngioma (86%), Rathke cleft cyst (9%), and cystic prolactinoma (5%). Preoperative clinical features included VF deficit (41%), VF deficit plus headache (36%), or headache alone (13%). For the aggregate cohort, statistically significant reduction in mean tumor-cyst volume for the cohort was observed at all follow-up visits beyond 3 months (all P < .01). At 5-year follow-up, cyst volume reduction was sustained in 82% of cases. The mean percent reduction in tumor-cyst volume was 77.2% (SD 16.8). Ninety-one percent of patients had stable or improved vision postoperatively. The overall proportion of patients with endocrine dysfunction preoperatively (59%) and postoperatively (68%) remained stable (P > .05). Treatment failure requiring conventional surgery occurred in 3 patients who received 90Y for cyst recurrence. CONCLUSION: Stereotactic treatment of CSMs with intracavitary 90Y is associated with sustained reduction in tumor-cyst volume, improved visual function, and stable endocrine function at 5-year follow-up.
- 23 April 2025
- Published by Wolters Kluwer Health in Neurosurgery
- Vol. 97 (5) , 1100-1107
Intracavitary Yttrium-90 Colloid Therapy for Cystic Sellar Masses: A Phase II Clinical Trial With 5-Year Follow-Up
BACKGROUND AND OBJECTIVES: Stereotactic intracavitary irradiation of cystic sellar masses (CSMs) with 90-Yttrium colloid (90Y) may mitigate significant morbidity and/or recurrence rates associated with traditional microsurgical resection. In this study, we aimed to prospectively assess the long-term effect of 90Y on tumor-cyst volume, endocrine, and vision outcomes after treatment of CSMs. METHODS: We conducted a Health Canada-approved, phase II, open label, prospective clinical trial. The primary indication for treatment was clinical evidence of mass effect on initial presentation or subsequent cyst enlargement. Patients underwent right frontal stereotactic insertion of 90Y (200 Gy to the cyst wall). Cyst volumes were measured using serial MRI. Visual field (VF) assessment and hypothalamic-pituitary hormone panel were obtained. Outcomes were collected postoperatively at 3, 9, and 24 months, then annually up to 5 years. RESULTS: Twenty-two patients (55% women, mean age = 63.6 years [SD 15.4]) received 90Y. The mean follow-up was 52 months (5-113). Primary diagnoses were the following: craniopharyngioma (86%), Rathke cleft cyst (9%), and cystic prolactinoma (5%). Preoperative clinical features included VF deficit (41%), VF deficit plus headache (36%), or headache alone (13%). For the aggregate cohort, statistically significant reduction in mean tumor-cyst volume for the cohort was observed at all follow-up visits beyond 3 months (all P < .01). At 5-year follow-up, cyst volume reduction was sustained in 82% of cases. The mean percent reduction in tumor-cyst volume was 77.2% (SD 16.8). Ninety-one percent of patients had stable or improved vision postoperatively. The overall proportion of patients with endocrine dysfunction preoperatively (59%) and postoperatively (68%) remained stable (P > .05). Treatment failure requiring conventional surgery occurred in 3 patients who received 90Y for cyst recurrence. CONCLUSION: Stereotactic treatment of CSMs with intracavitary 90Y is associated with sustained reduction in tumor-cyst volume, improved visual function, and stable endocrine function at 5-year follow-up.
- Open Access
- 1 January 2025
- Published by SAGE Publications in Global Spine Journal
- Vol. 15 (1_suppl) , 47S-80S
A Critical Appraisal of the Application of Frailty and Sarcopenia in the Spinal Oncology Population
Study Design: Systematic review and clinimetric analysis. Objectives: Frailty and sarcopenia predict worse surgical outcomes among spinal degenerative and deformity-related populations; this association is less clear in the context of spinal oncology. Here, we sought to identify frailty and sarcopenia tools applied in spinal oncology and appraise their clinimetric properties. Methods: A systematic review was conducted from January 1 st , 2000, until June 2022. Study characteristics, frailty tools, and measures of sarcopenia were recorded. Component domains, individual items, cut-off values, and measurement techniques were collected. Clinimetric assessment was performed according to Consensus-based Standards for Health Measurement Instruments. Results: Twenty-two studies were included (42 514 patients). Seventeen studies utilized 6 frailty tools; the three most employed were the Metastatic Spine tumor Frailty Index (MSTFI), Modified Frailty Index-11 (mFI-11), and the mFI-5. Eight studies utilized measures of sarcopenia; the three most common were the L3-Total Psoas Area (TPA)/Vertebral Body Area (VBA), L3-TPA/Height 2 , and L3-Spinal Muscle Index (L3-Cross-Sectional Muscle Area/Height 2 ). Frailty and sarcopenia measures lacked or had uncertain content and construct validity. Frailty measures were objective except the Johns-Hopkins Adjusted Clinical Groups. All tools were feasible except the Hospital Frailty Risk Score (HFRS). Positive predictive validity was observed for the HFRS and in select studies employing the mFI-5, MSTFI, and L3-TPA/VBA. All frailty tools had floor or ceiling effects. Conclusions: Existing tools for evaluating frailty and sarcopenia among patients undergoing surgery for spinal tumors have poor clinimetric properties. Here, we provide a pragmatic approach to utilizing existing frailty and sarcopenia tools, until more clinimetrically robust instruments are developed.
- 1 January 2025
- Published by SAGE Publications in Global Spine Journal
- Vol. 15 (1_suppl) , 47S-80S
Open AccessA Critical Appraisal of the Application of Frailty and Sarcopenia in the Spinal Oncology Population
Study Design: Systematic review and clinimetric analysis. Objectives: Frailty and sarcopenia predict worse surgical outcomes among spinal degenerative and deformity-related populations; this association is less clear in the context of spinal oncology. Here, we sought to identify frailty and sarcopenia tools applied in spinal oncology and appraise their clinimetric properties. Methods: A systematic review was conducted from January 1 st , 2000, until June 2022. Study characteristics, frailty tools, and measures of sarcopenia were recorded. Component domains, individual items, cut-off values, and measurement techniques were collected. Clinimetric assessment was performed according to Consensus-based Standards for Health Measurement Instruments. Results: Twenty-two studies were included (42 514 patients). Seventeen studies utilized 6 frailty tools; the three most employed were the Metastatic Spine tumor Frailty Index (MSTFI), Modified Frailty Index-11 (mFI-11), and the mFI-5. Eight studies utilized measures of sarcopenia; the three most common were the L3-Total Psoas Area (TPA)/Vertebral Body Area (VBA), L3-TPA/Height 2 , and L3-Spinal Muscle Index (L3-Cross-Sectional Muscle Area/Height 2 ). Frailty and sarcopenia measures lacked or had uncertain content and construct validity. Frailty measures were objective except the Johns-Hopkins Adjusted Clinical Groups. All tools were feasible except the Hospital Frailty Risk Score (HFRS). Positive predictive validity was observed for the HFRS and in select studies employing the mFI-5, MSTFI, and L3-TPA/VBA. All frailty tools had floor or ceiling effects. Conclusions: Existing tools for evaluating frailty and sarcopenia among patients undergoing surgery for spinal tumors have poor clinimetric properties. Here, we provide a pragmatic approach to utilizing existing frailty and sarcopenia tools, until more clinimetrically robust instruments are developed.
- Open Access
Imaging blood–brain barrier dysfunction in drug‐resistant epilepsy: A multi‐center feasibility study
Objective: Blood–brain barrier dysfunction (BBBD) has been linked to various neurological disorders, including epilepsy. This study aims to utilize dynamic contrast‐enhanced magnetic resonance imaging (DCE‐MRI) to identify and compare brain regions with BBBD in patients with epilepsy (PWE) and healthy individuals.Methods: We scanned 50 drug‐resistant epilepsy (DRE) patients and 58 control participants from four global specialized epilepsy centers using DCE‐MRI. The presence and extent of BBBD were analyzed and compared between PWE and healthy controls.Results: Both greater brain volume and higher number of brain regions with BBBD were significantly present in PWE compared to healthy controls (p < 10−7). No differences in total brain volume with BBBD were observed in patients diagnosed with either focal seizures or generalized epilepsy, despite variations in the affected regions. Overall brain volume with BBBD did not differ in PWE with MRI‐visible lesions compared with non‐lesional cases. BBBD was observed in brain regions suspected to be related to the onset of seizures in 82% of patients (n = 39) and was typically identified in, adjacent to, and/or in the same hemisphere as the suspected epileptogenic lesion (n = 10).Significance: These findings are consistent with pre‐clinical studies that highlight the role of BBBD in the development of DRE and identify microvascular stabilization as a potential therapeutic strategy.
Open AccessImaging blood–brain barrier dysfunction in drug‐resistant epilepsy: A multi‐center feasibility study
Objective: Blood–brain barrier dysfunction (BBBD) has been linked to various neurological disorders, including epilepsy. This study aims to utilize dynamic contrast‐enhanced magnetic resonance imaging (DCE‐MRI) to identify and compare brain regions with BBBD in patients with epilepsy (PWE) and healthy individuals.Methods: We scanned 50 drug‐resistant epilepsy (DRE) patients and 58 control participants from four global specialized epilepsy centers using DCE‐MRI. The presence and extent of BBBD were analyzed and compared between PWE and healthy controls.Results: Both greater brain volume and higher number of brain regions with BBBD were significantly present in PWE compared to healthy controls (p < 10−7). No differences in total brain volume with BBBD were observed in patients diagnosed with either focal seizures or generalized epilepsy, despite variations in the affected regions. Overall brain volume with BBBD did not differ in PWE with MRI‐visible lesions compared with non‐lesional cases. BBBD was observed in brain regions suspected to be related to the onset of seizures in 82% of patients (n = 39) and was typically identified in, adjacent to, and/or in the same hemisphere as the suspected epileptogenic lesion (n = 10).Significance: These findings are consistent with pre‐clinical studies that highlight the role of BBBD in the development of DRE and identify microvascular stabilization as a potential therapeutic strategy.